COUNTERPOINT: Urologists should take an active role in the diagnosis and treatment of hypogonadism in the aging male

Richard W. Casey, MD

The Male Health Centre, Oakville, Ontario, Canada

CASEY RW. COUNTERPOINT: Urologists should take an active role in the diagnosis and treatment of hypogonadism in the aging male. The Canadian Journal of Urology. 2002;9(6):1681-1683.

The recent interest in the potential applications of new testosterone preparations has stimulated industry and physicians to develop indications for their use. Despite little scientific evidence to support the widespread application of testosterone in aging men, a clinical symptom complex called Partial Androgen Deficiency in the Aging Male (PADAM) has been described. Many of these symptoms can be successfully treated without testosterone administration. The author suggests that prospective randomized clinical trials are necessary to support the application of testosterone in the PADAM patient and until then physicians take a more balanced approach in this patient population.

Key Words: andropause, testosterone, libido, osteoporosis, replacement therapy, erectile dysfunction

The recent introduction of a variety of novel testosterone preparations have stimulated the medical community to consider their application in a subpopulation of aging males. Apparently, a significant number of men might benefit from additional testosterone (T) to correct falling levels that accompany aging.

Androgen deficiency in the aging male (ADAM) or andropause is purported to be a common condition in males over 40 characterized by a constellation of symptoms including increased mental irritability, decreased muscle strength, and libido, and vasomotor manifestations loosely correlated with falling T levels. In addition, the accompanying effects of this hypogonadal state include osteopenia and possibly increased cardiac morbidity.[1]

If we use current acceptable T ranges, 7% of men aged 40-50, 20% aged 60-80 and 35% of men over 80 would have below normal serum T.[2] Not all these men will exhibit the ADAM symptom complex although few men over the age of 40 will not admit to decrease in sexual appetite and energy levels, contributing to the difficulty in establishing a proper diagnosis.[3] Without significant scientific evidence to support this therapeutic intervention, physicians have been asked to consider treating these men with testosterone. In addition to declining T levels with age, many other factors such as a decrease in adrenal hormones (dehydroepiandrosterone sulfate) and growth hormone as well as a decrease in physical activity, are thought to play a role in these age related changes.[4]

Little is known about the outcome of long-term treatment of older men with testosterone. In elderly hypogonadal men, testosterone administration positively affects biochemical markers of muscle and bone metabolism and can increase lumbar spinal bone density.[5] We do not have clear evidence that this translates to a reduction in age related falls and fractures. At the present time there are good therapeutic interventions, supported by prospective well-controlled trials, that can increase bone density to the same degree as T administration without the need for daily drug administration.[5]

The relationship between testosterone and libido is strong, but inconsistent. Despite the significant

Accepted for publication October 2002

Address correspondence to Dr. Richard W. Casey, The Male Health Centre, 1235 Trafalgar Road, Suite 407, Oakville, Ontario, L6J 3P1

difference in bioavailable T levels in older men, complaints of decreased libido are rare, the most common sexual complaint being erectile dysfunction. Depression is the most common clinical condition producing decreased libido in all ages.[6] Depressed men with significantly reduced T levels may benefit from addition of T to antidepressant therapy, but again the results are variable and scientific support scarce. There is considerable overlap in the symptom complex between depression and ADAM and urologists, more comfortable with surgical problems and solutions, may not be the best suited to differentiate these two conditions.

While there is little evidence that testosterone replacement increases the risk of prostate cancer, there are no controlled trials that suggest this practice is entirely without risk.[7] Testosterone is contraindicated in the presence of prostate cancer and long-term administration places a significant burden on the physician to insure their patients do not develop prostate cancer while on T. While evidence is lacking that benign prostatic hyperplasia may be accelerated by T administration, aromatization of excess T to estrogens could exacerbate underlying breast carcinoma.[1] Other potential side effects of long-term T administration include an increased hematocrit, exacerbation of sleep apnea, gynecomastia, suppression of spermatogenesis and fluid retention.[7] In addition, there is a significant risk of self overmedication , particularly in those men with body dysmorphic syndrome(personal observation). While these men tend to present in their 20's, there remains a large population of dissatisfied men who will seek T as a solution to their self image obsessions. Widespread use of T will facilitate access by this group.

The lack of consensus on what constitutes the diagnosis of biochemical hypogonadism further weakens our diagnostic and therapeutic abilities. Low levels of testosterone, free testosterone or bioavailable testosterone correlate poorly with andropausal symptoms[8] and some authors suggest that the symptoms alone are sufficient for a trial of testosterone therapy in the presence of low normal levels. Without good endpoints, a trial of therapy serves little diagnostic purpose and is costly.

No validated tools exist to assist the physician in their assessment of andropause and the evaluation of treatment response. The Morley questionnaire appears in a number of educational publications and papers but has not been appropriately validated and is not designed to assess treatment response.[9] This tool has a sensitivity of 88% and a specificity of 40%. These figures suggest that, if widely used by physicians, a false positive diagnosis could occur in up to 40% of men tested if applied as a screening tool. Further work is necessary to develop a more specific questionnaire that is sensitive to treatment effects and can be used as a diagnostic aid.

Another source of interest in T replacement comes from our experience with female patients. The use of hormone replacement therapy (HRT) in menopause remains controversial and the long-term use of HRT may increase the risk of breast and endometrial cancer. Despite over 20 years of widespread application, many physicians remain unconvinced that the benefits from HRT outweigh the risks and at best, HRT may be a short-term solution for the symptoms women experience during menopause. The use of antiosteoporotic agents, weight-bearing exercise, local estrogens for vaginal atrophy and dietary modifications present an alternative to long term HRT in this population.

The cost of widespread T replacement for men would be astronomical, the cost effectiveness unknown. In addition, deficiencies in our diagnostic capabilities insure that a large number of men will be unnecessarily exposed to 3 to 6 months of therapy with no change in their initial complaints.

Our heightened awareness of erectile dysfunction (ED) has clearly benefited the T industry by increasing the number of men discussing sexual difficulties with their physicians. Unfortunately, T has traditionally been associated with sexual performance and is a frequent request of patients pursuing improvements in their sexual health. The success of T therapy in men with reduced libido is variable and dependant on an appropriate initial diagnosis.[10] The effort necessary to sort out the other psychosocial and lifestyle issues to insure a proper diagnosis is not one physicians readily accept. ED patients are even more resistant to counseling and lifestyle modifications[10] It is likely that the same pattern will be seen in the andropausal patient.

Why then, in the face of a poorly defined clinical entity (ADAM), with no reliable marker (serum T determinations), the absence of a tool to determine treatment benefits and with little long-term efficacy and safety data when used in this population are we being asked to consider HRT for men. Urologists have little background in the assessment and treatment of osteoporosis or depression and few are willing to spend the necessary time counseling these patients. Is the explosion of T propaganda a result of an unmet need identified by physicians or an industry driven syndrome. In my opinion it is the latter.

Testosterone is a drug looking for a broader indication. In clearly hypogonadal men with symptoms of testosterone deficiency and an understanding of the clinical endpoints expected with treatment, replacement therapy can provide an improvement in quality of life, restoration of normal sexual function, and may reduce the long-term sequele associated with T deficiency such as osteoporosis. This patient population is relatively easy to define. The andropausal population isn't. Defining it by a trial of therapy is not only unscientific but also unsafe. The development of new delivery systems for T has been the major impetus for its use, not the demand for a solution to the ADAM problem. Fortunately, we have begun to narrow our indications for T replacement as we examine our patient's response to therapy. All of us who treat this population are involved in a virtual uncontrolled prospective, single arm study funded by the patient and our government's health care budget.

Properly controlled clinical trials together with the development of validated instruments and a reliable marker for ADAM is necessary before T therapy should be accepted. A scale similar to the International Index of Erectile Function (IIEF) that includes all affected domains would be invaluable in assessing and treating this population. Monies spent on 'educational forums' for andropause, Continuing Medical Educational events and conference dollars targeted to spreading the spin on T therapy could, in part, be directed to the scientific community. There has been a significant 'direct to consumer' advertising effort and a variety of popular web sites written by physicians and supported by industry touting the potential positive effects of T in all men. Physicians rely on industry to assist them with their educational needs and 'opinion leaders' to help design these courses to provide useful, evidence based knowledge. At the present time, our opinion leaders have little scientific ammunition to bolster the barrage of T applications. Many of the symptoms associated with the andropausal syndrome can be alleviated with attention to diet, exercise, education and counseling. Osteoporosis can be treated with a number of agents and it is unlikely that the cardiac risk argument will withstand the test of time. Unfortunately both physicians and patient prefer an 'interview ending' prescription rather a reconfiguration of their lifestyles.

Should urologists be actively involved in the assessment and treatment of the hypogonadal male? Certainly. Should this include that population presently designated andropausal by industry and associated opinion leaders. No, not until an effort is made to provide physicians with supportive clinical data and validated assessment instruments necessary to safely introduce T therapy to the targeted populations. Physicians should insist that industry, not the patient, pay the price of admission. □

References

1. Bain J. Andropause. Testosterone replacement therapy for aging men. *Can Fam Physician* 2001;47:91-97.
2. Vermeulen A, Kaufman JM. Ageing of the Hypothalamo-pituitary-testicular axis in men. *Horm Res* 1995;43(1-3):25-28.
3. Musitelli S. The Ageing Male in Literature. *The Aging Male* 2001;4:170-187.
4. Vermeulen A. Androgen replacement therapy in the aging male-a critical evaluation. *J Clin Endocrinol Metab* 2001;86(6):2380-2390.
5. Behre HM, Kliesch S, Leifke E, Link TM, Niesch E. Long-term effect of testosterone therapy on Bone mineral density in hypogonadal men. *J Clin Endocrinol Metab* 1997:82(8):2386-2390.
6. Barrrett-Connor E, Von Mahler DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: The Rancho Bernardo Study. *J Clin Endocrinol Metab* 1999,:84(2):573-577.
7. Morales A, Heaton JP, Carson CC. Andropause: a misnomer for a true clinical entity. J Urol 2000;163(3):705-712.
8. Tremblay RR, Morales A. Canadian practice recommendation for screening, monitoring and treating men affected by andropause. *Aging Male* 1998;1(3):213-218.
9. Morley JE, Charlton E, Patrick P , Kaiser FE, Cadea P, McCready D et al. Validation of a screening questionairre for androgen deficiency in aging males. *Metabolism* 2000; 49(9):1239-1242.
10. Lee JC, Surridge DHC, Morales A, Heaton JPW. Erectile Dysfunction: The perpectives of patients and partners on counseling. *J Sex Reprod Med* 2002;2(1):11-15.